TUBE OCCLUSION SYSTEM
Femigard vision - striving for new horizon in female fertility and sterility.
Founded in 2019, backed by Sanara Ventures and the Israeli Innovation Authority
Established expertise in medical device development, with top tier industry collaborators
A novel concept for fallopian tubes occlusion.
Applicable to a wide range
Expected during 2022
Supporting clinical validation
Unique technology protection. establishing significant entry barrier Currently at PCT stage
Provide unique medical solution for clinical needs
Non hormonal reversible tubal occlusion in office procedure
Improving pregnancy implantation success rates in patients with tubal Hydrosalpinx